The most dangerous moment in biotech fundraising is not when an investor says no. It is when they say nothing at all, no feedback, no next steps, just an inbox that stays quiet week after week. For biotech founders, this silence quickly becomes a mental trap. 👉 Every unanswered message invites a new story.   Maybe the science was not compelling enough. Maybe the company is too early. Maybe the market shifted. Maybe the investor never really understood the technology in the f

👉 In biotech, it is widely assumed that strong data naturally leads to strong execution . If experiments are rigorous and results are validated, progress should be inevitable. This belief is deeply embedded in scientific culture, and it feels rational. Yet in reality, biotech execution rarely breaks because of weak data . It breaks because teams avoid making hard choices. More precisely, they avoid explicitly acknowledging the tradeoffs that shape every execution path . 👉 F